HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.

Abstract
Previously, it was shown that a novel 4-(N)-stearoyl gemcitabine nanoparticle formulation was more effective than gemcitabine hydrochloride in controlling the growth of model mouse or human tumors pre-established in mice. In the present study, the feasibility of targeting the stearoyl gemcitabine nanoparticles (GemC18-NPs) into tumor cells that over-express epidermal growth factor receptor (EGFR) to more effectively control tumor growth was evaluated. EGFR is over-expressed in a variety of tumor cells, and EGF is a known natural ligand of EGFR. Recombinant murine EGF was conjugated onto the GemC18-NPs. The ability of the EGF to target the GemC18-NPs to human breast adenocarcinoma cells that expressed different levels of EGFR was evaluated in vitro and in vivo. In culture, the extent to which the EGF-conjugated GemC18-NPs were taken up by tumor cells was correlated to the EGFR density on the tumor cells, whereas the uptake of untargeted GemC18-NPs exhibited no difference among those same cell lines. The relative cytotoxicity of the EGF-conjugated GemC18-NPs to tumor cells in culture was correlated to EGFR expression as well. In vivo, EGFR-over-expressing MDA-MB-468 tumors in mice treated with the EGF-conjugated GemC18-NPs grew significantly slower than in mice treated with untargeted GemC18-NPs, likely due to that the EGF-GemC18-NPs were more anti-proliferative, anti-angiogenic, and pro-apoptotic. Fluorescence intensity data from ex vivo imaging showed that the EGF on the nanoparticles helped increase the accumulation of the GemC18-NPs into MDA-MB-468 tumors pre-established in mice by more than 2-fold as compared to the un-targeted GemC18-NPs. In conclusion, active targeting of the GemC18-NPs into EGFR-over-expressed tumors can further enhance their anti-tumor activity.
AuthorsMichael A Sandoval, Brian R Sloat, Dharmika S P Lansakara-P, Amit Kumar, B Leticia Rodriguez, Kaoru Kiguchi, John Digiovanni, Zhengrong Cui
JournalJournal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 157 Issue 2 Pg. 287-96 (Jan 30 2012) ISSN: 1873-4995 [Electronic] Netherlands
PMID21871505 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2011 Elsevier B.V. All rights reserved.
Chemical References
  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Epidermal Growth Factor
  • Ovalbumin
  • ErbB Receptors
  • Gemcitabine
Topics
  • Animals
  • Antimetabolites, Antineoplastic (administration & dosage)
  • Cell Line, Tumor
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Epidermal Growth Factor (administration & dosage)
  • ErbB Receptors (metabolism)
  • Humans
  • Mice
  • Mice, Nude
  • Molecular Targeted Therapy
  • Nanoparticles (administration & dosage)
  • Neoplasms (metabolism, pathology, therapy)
  • Ovalbumin (administration & dosage)
  • Tumor Burden (drug effects)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: